



Fax Referral To: 800-323-2445

Phone: 866-278-6634

Nexavar® (sorafenib) Enrollment Form For Blue Cross Blue Shield of Rhode Island Members

Date: Needs by Date (Please Specify):

Ship to: Patient Office Other:

PATIENT INFORMATION

(Complete the following or send patient demographic sheet)

Patient Name: Address: City, State, Zip: Home Phone: Alternate Phone: SS #: Insurance ID: Date of Birth: Gender:

PRESCRIBER INFORMATION

Prescriber's Name: State License #: DEA #: Group or Hospital: Address: City, State Zip: Phone: Fax: Contact Person: Contact Phone: UPIN: NPI #:

INSURANCE INFORMATION (If available, please copy and attach the front and back of insurance and prescription drug card)

Primary Insurance: Subscriber: Subscriber ID#: Name of Insurer: Blue Cross Blue Shield of RI Secondary Insurance: Subscriber: Subscriber ID#: Name of Insurer:

STATEMENT OF MEDICAL NECESSITY for BCBS of Rhode Island Members

Diagnosis: 189.0 Renal cell carcinoma Other: Date of Diagnosis:

APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY.

NOTE: Any areas not filled out are considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request.

- Has the patient been diagnosed with Renal Cell Carcinoma? OR Has the patient been diagnosed with Kidney Cancer?

Note: The following compendia, American Hospital Formulary Service, U.S. Pharmacopeia Dispensing Information, National Comprehensive Cancer Network NCCN, and Drug & Biologics Compendium™ Category of Evidence and Consensus are considered during prior authorization review if the drug is being prescribed for a condition not listed above.

Medical Necessity (please attach all supporting documentation):

PRESCRIPTION INFORMATION

Table with 5 columns: Medication, Strength, Directions, Quantity, Refills. Row 1: Nexavar (sorafenib), 200mg, Take two tablets (400mg) by mouth twice a day at least one hour before or two hours after eating.

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law.